Borosil Scientific Limited Earnings Summary — Q4 FY2026

• Revenue growth was driven by the Scientific segment, which saw quarterly revenue rise to ₹9,844.79 lakhs compared to ₹8,623.96 lakhs YoY.
• The company reported a significant sequential jump in Net Profit, more than doubling from Q3 FY26 (₹1,021.07 lakhs) to Q4 FY26 (₹2,153.57 lakhs).
• Operating performance improved markedly with Profit Before Tax (pre-exceptional) margins reaching 21.87% in Q4 vs 16.59% YoY.
• A one-time exceptional charge of ₹191.51 lakhs was recorded in the previous quarter (Q3) related to new Labour Code legislation impacts.
• The Board is seeking an enabling resolution to raise up to ₹250 crores via QIP, FCCBs, or other modes to fund future requirements.
• The Glassware segment continues to show losses at the EBIT level (₹172.63 lakhs loss in Q4), though losses narrowed from the previous year.
• Working capital remains intensive but the balance sheet is characterized by high liquidity, with current investments at ₹12,243.92 lakhs.
• Management continuity is emphasized by the re-appointment of Mr. Vinayak Patankar as CEO for another three-year term.

Management is focusing on organic growth within the Scientific and Laboratory Glass segments and intends to maintain its leadership in QC-intensive sectors like pharmaceuticals. The fund-raising resolution indicates an appetite for capital expenditure or inorganic opportunities.

Improving

The sharp recovery in sequential margins and profitability, alongside steady revenue growth in the core Scientific segment, suggests strengthening operational leverage.

The company appears well-positioned to capitalize on pharmaceutical R&D spending. While the Glassware segment is still a drag on total profitability, the core Scientific segment is delivering high margins that support the overall bottom line. The proposed ₹250 Cr fundraise suggests a shift toward more aggressive growth scaling.